DELFI to Share Clinical Utility Data at ATS 2026

Key Takeaways

• DELFI's ATS program centers on the late-breaking FIRSTLUNG presentation, the first interventional study designed to evaluate the clinical utility of a blood-based test in the lung cancer screening pathway.
• Other presentations will focus on health system implementation, uptake and adherence barriers, and the feasibility of at-home blood collection in under-resourced communities.

DELFI Diagnostics will present five abstracts at ATS 2026 in Orlando, with a late-breaking oral presentation from the L301 FIRSTLUNG study at the center.

The cluster-randomized interventional trial is exploring whether offering blood-based lung cancer testing with FirstLook Lung or low-dose computed tomography can increase overall screening rates, including in primary care settings. The company also describes it as the first interventional study designed to evaluate the clinical utility of a blood-based test in the lung cancer screening pathway.

Beyond the late-breaking session, DELFI's ATS slate includes real-world implementation data from health systems already using FirstLook Lung in clinical practice. Presenters will share insights on at-home blood collection for lung cancer screening in under-resourced communities, along with presentations addressing uptake, completion, and adherence barriers.

Clinical utility findings from FIRSTLUNG are investigational and do not constitute FDA clearance or approval.